H.C. Wainwright lowered the firm’s price target on Codexis to $9 from $15 and keeps a Buy rating on the shares post the Q4 results.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CDXS:
- Codexis, Nestle Health Science announce interim CDX-7108 results
- Codexis sees FY23 revenue $63M-$68M, consensus $91.98M
- Codexis reports Q4 EPS (19c), consensus (23c)
- Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
- Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™